Argent BioPharma Enters Germany - Europe's Largest Market

Rhea-AI Summary

Argent BioPharma (ASX: RGT, OTCQB: RGTLF) has announced its entry into the German pharmaceutical market, securing initial purchase orders for CannEpil® and CogniCann® following regulatory approval. Germany, being Europe's largest healthcare market, represents a significant commercial milestone for the company's European expansion strategy.

The clinical-stage biopharmaceutical company has also completed the transfer of its EU GMP-certified manufacturing facilities in Slovenia and Malta to third-party operators. This operational restructuring is expected to generate annual cost savings of over $1 million while maintaining GMP compliance. The freed capital will be directed towards accelerating R&D initiatives and clinical trials across core therapeutic programs.

Positive

• Entry into Germany, Europe's largest healthcare market
• Secured initial purchase orders for CannEpil® and CogniCann®
• Over $1 million annual cost savings from manufacturing facilities transfer
• Maintained GMP compliance while reducing infrastructure overhead

Negative

• Divestment of manufacturing control through transfer to third-party operators

Strategic Expansion Paired with Over $1M in Annual Cost Savings from Operational Restructuring

PERTH, Australia, April 23, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. Germany, as the largest healthcare market in Europe, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.

In parallel, the Company has successfully completed the transfer of its EU GMP-certified manufacturing facilities in Slovenia and Malta to trusted third-party operators. This strategic operational shift allows Argent to maintain GMP compliance while reducing infrastructure overhead, resulting in annual operational cost savings exceeding USD $1 million. These efficiencies free up capital to further accelerate R&D initiatives and clinical trials across core therapeutic programs.

These achievements reflect Argent BioPharma's broader transformation strategy—centered on fully proprietary, neuroimmune drug development, in-house innovation, and sustainable global scalability. The Company remains focused on advancing its therapeutic pipeline while deepening market penetration across high-value regions.

About Argent BioPharma
Argent BioPharma Ltd. (ASX: RGT) develops proprietary therapeutics targeting central nervous system (CNS) and autoimmune disorders using its Neuro-Immune Modulatory (NIM) platform. Lead assets include CannEpil®, CogniCann®, and CimetrA®, which are now entering major European markets as part of a targeted international growth plan.

Contact:
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

View original content:https://www.prnewswire.com/news-releases/argent-biopharma-enters-germany--europes-largest-market-302435972.html

SOURCE Argent BioPharma Ltd.

FAQ

What is the expected annual cost savings for Argent BioPharma (RGTLF) from its operational restructuring?

Argent BioPharma expects to achieve annual operational cost savings exceeding USD $1 million through the transfer of its EU GMP-certified manufacturing facilities to third-party operators.

Which products has Argent BioPharma (RGTLF) received purchase orders for in Germany?

Argent BioPharma has received initial purchase orders for CannEpil® and CogniCann® in the German market.

How will RGTLF use the cost savings from its manufacturing facilities transfer?

The cost savings will be used to accelerate R&D initiatives and clinical trials across core therapeutic programs.

Which manufacturing facilities has Argent BioPharma (RGTLF) transferred to third-party operators?

Argent BioPharma has transferred its EU GMP-certified manufacturing facilities in Slovenia and Malta to third-party operators.